Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:COEP OTCMKTS:CVSI OTCMKTS:IGXT NASDAQ:INKT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCOEPCoeptis Therapeutics$11.26+15.3%$8.91$2.31▼$13.70$34.35M-0.63120,633 shs142,369 shsCVSICV Sciences$0.04+2.9%$0.03$0.02▼$0.06$6.47M0.6259,041 shs85,715 shsIGXTIntelGenx Technologies$0.17$0.17$0.09▼$0.22$29.17M2.47N/AN/AINKTMiNK Therapeutics$23.25+0.6%$9.85$4.56▼$76.00$92.11M0.19240,307 shs1.86 million shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCOEPCoeptis Therapeutics+15.25%+18.53%+37.15%+12.60%+93.07%CVSICV Sciences+2.86%-10.00%+23.71%+29.50%-26.53%IGXTIntelGenx Technologies0.00%0.00%0.00%0.00%0.00%INKTMiNK Therapeutics+0.61%+200.78%+210.41%+204.72%+121.43%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCOEPCoeptis Therapeutics0.5022 of 5 stars0.03.00.00.02.21.70.0CVSICV SciencesN/AN/AN/AN/AN/AN/AN/AN/AIGXTIntelGenx TechnologiesN/AN/AN/AN/AN/AN/AN/AN/AINKTMiNK Therapeutics2.5284 of 5 stars3.23.00.00.02.81.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCOEPCoeptis Therapeutics 0.00N/AN/AN/ACVSICV Sciences 0.00N/AN/AN/AIGXTIntelGenx Technologies 0.00N/AN/AN/AINKTMiNK Therapeutics 2.33Hold$37.5061.29% UpsideCurrent Analyst Ratings BreakdownLatest CVSI, IGXT, COEP, and INKT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/15/2025INKTMiNK TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Neutral$35.007/11/2025INKTMiNK TherapeuticsWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Market Perform(Data available from 7/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCOEPCoeptis TherapeuticsN/AN/AN/AN/A$1.61 per shareN/ACVSICV Sciences$15.70M0.42N/AN/A$0.01 per share3.60IGXTIntelGenx Technologies$1.04M28.05N/AN/A($0.07) per share-2.39INKTMiNK TherapeuticsN/AN/AN/AN/A($4.94) per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCOEPCoeptis Therapeutics-$10.88M-$5.80N/A∞N/AN/A-282.39%-127.23%N/ACVSICV Sciences-$2.39MN/A0.00∞N/A-12.25%-89.43%-22.75%N/AIGXTIntelGenx Technologies-$9.93M-$0.06N/A∞N/AN/AN/AN/AN/AINKTMiNK Therapeutics-$9.51M-$2.52N/AN/AN/AN/AN/A-140.72%8/12/2025 (Estimated)Latest CVSI, IGXT, COEP, and INKT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2025Q2 2025INKTMiNK Therapeutics-$0.45N/AN/AN/AN/AN/A5/15/2025Q1 2025INKTMiNK Therapeutics-$0.61-$0.70-$0.09-$0.70N/AN/A5/14/2025Q1 2025COEPCoeptis TherapeuticsN/A-$1.11N/A-$1.11N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCOEPCoeptis TherapeuticsN/AN/AN/AN/AN/ACVSICV SciencesN/AN/AN/AN/AN/AIGXTIntelGenx TechnologiesN/AN/AN/AN/AN/AINKTMiNK TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCOEPCoeptis Therapeutics0.020.820.82CVSICV Sciences0.261.140.30IGXTIntelGenx TechnologiesN/AN/AN/AINKTMiNK TherapeuticsN/A0.300.30Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCOEPCoeptis Therapeutics13.88%CVSICV SciencesN/AIGXTIntelGenx TechnologiesN/AINKTMiNK Therapeutics2.87%Insider OwnershipCompanyInsider OwnershipCOEPCoeptis Therapeutics24.25%CVSICV Sciences3.80%IGXTIntelGenx Technologies42.05%INKTMiNK Therapeutics22.48%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCOEPCoeptis Therapeutics23.51 million2.66 millionNot OptionableCVSICV Sciences70184.79 million177.77 millionNot OptionableIGXTIntelGenx Technologies38174.66 million101.21 millionNot OptionableINKTMiNK Therapeutics303.99 million3.09 millionNo DataCVSI, IGXT, COEP, and INKT HeadlinesRecent News About These CompaniesMiNK Therapeutics (NASDAQ:INKT) Cut to Neutral at HC Wainwright3 hours ago | americanbankingnews.comMiNK Therapeutics: Moving Out Of The Hunt's Early DaysJuly 16 at 6:52 AM | seekingalpha.comWilliam Blair Downgrades MiNK Therapeutics (INKT)July 16 at 6:52 AM | msn.comHC Wainwright Reiterates Neutral Rating for MiNK Therapeutics (NASDAQ:INKT)July 15 at 11:19 AM | marketbeat.comMiNK Therapeutics Announces Frontiers in Immunology Publication Highlighting iNKT Cells as a Dual-Function Platform Key to Overcoming Barriers in Solid Tumor Cell TherapyJuly 15 at 8:42 AM | globenewswire.comMiNK Therapeutics Announces Frontiers in Immunology Publication Highlighting iNKT Cells as a Dual-Function Platform Key to Overcoming Barriers in Solid Tumor Cell TherapyJuly 15 at 8:42 AM | globenewswire.comMiNK Therapeutics Enters $50M Sales Agreement with B. RileyJuly 15 at 7:48 AM | tipranks.comMiNK Therapeutics Shares Drop Sharply Following William Blair DowngradeJuly 14, 2025 | msn.comMiNK Therapeutics stock falls after William Blair downgradeJuly 14, 2025 | finance.yahoo.comPromising Small Cap Stocks To Watch Now - July 13thJuly 13, 2025 | marketbeat.comPharmaceutical Stocks Worth Watching - July 13thJuly 13, 2025 | marketbeat.comMiNK Therapeutics Announces Publication of Complete Remission Following ...July 13, 2025 | seekingalpha.comMiNK Therapeutics: AgenT-797 Solidifies Itself As iNKT Cell Therapy With Latest CR DataJuly 13, 2025 | seekingalpha.comPromising Medical Stocks To Add to Your Watchlist - July 13thJuly 13, 2025 | marketbeat.comWhy Is MiNK Therapeutics Stock (INKT) Up 190% Today?July 12, 2025 | msn.comMiNK Therapeutics Announces Publication of Complete Remission Following Allogeneic iNKT Cell ...July 11, 2025 | bakersfield.comBMiNK Therapeutics stock soars after cancer remission breakthroughJuly 11, 2025 | investing.comWhy Did INKT Stock Skyrocket in Today’s Premarket Trading?July 11, 2025 | tokenist.comTMiNK Therapeutics Shares Surge After Remission Case Published in Scientific JournalJuly 11, 2025 | marketwatch.comMiNK Therapeutics Stock Soars On Patient Receiving Full Remission In Testicular Cancer With Investigational Cell TherapyJuly 11, 2025 | msn.comMiNK Therapeutics Shares Skyrocket After Landmark Cancer Remission ResultJuly 11, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCVSI, IGXT, COEP, and INKT Company DescriptionsCoeptis Therapeutics NASDAQ:COEP$11.26 +1.49 (+15.25%) Closing price 07/17/2025 04:00 PM EasternExtended Trading$11.33 +0.07 (+0.62%) As of 04:59 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Coeptis Therapeutics Holdings, Inc., a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy. The company also offers its drugs for acute myeloid leukemia and acute respiratory diseases. Coeptis Therapeutics Holdings, Inc. has co-development agreement Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson's Disease. The company was founded in 2017 and is headquartered in Wexford, Pennsylvania.CV Sciences OTCMKTS:CVSI$0.04 +0.00 (+2.86%) As of 07/17/2025 03:19 PM EasternCV Sciences, Inc. develops, manufactures, markets, and sells herbal supplements and hemp-based cannabidiol (CBD) in North America. It operates in two segments, Consumer Products and Specialty Pharmaceutical. The company offers its products under the PlusCBD, ProCBD, HappyLane, CVAcute, CVDefense, and PlusCBD Pet brands in the health care market sector, including nutraceutical, beauty care, specialty foods, and pet products through its websites, elect distributors, brick and mortar retailers, and select e-tailers. It is also developing cannabinoids intended to treat medical indications, including CVSI-007 that combines CBD and nicotine for the treatment of smokeless tobacco use and addiction. The company was formerly known as CannaVest Corp. and changed its name to CV Sciences, Inc. in January 2016. CV Sciences, Inc. was incorporated in 2010 and is based in San Diego, California.IntelGenx Technologies OTCMKTS:IGXT$0.17 0.00 (0.00%) As of 05/27/2025IntelGenx Technologies Corp., a drug delivery company, focuses on the development and manufacturing of novel oral thin film products for the pharmaceutical market. It offers INT0008/2008, a Rizatriptan oral film product for the treatment of migraine; INT0046/2018 and INT0055/2021 are for adult use; INT0007/2006, an oral film product for treatment of erectile dysfunction; INT0043/2015, an oral film containing montelukast for treatment of Alzheimer and Parkinsons; INT0027/2011 to treat opioid addition; INT0010/2006 for treatment of neuropathic pain and nausea in cancer patients undergoing chemotherapy; INT0036/2013, an oral film product for schizophrenia or bipolar 1 disorder; and INT0048/2020 for animal health. It is also develops INT0039/2013 for pain; and INT0053/2020 for the treatment of resistant depression. The company has licensing, development, and supply agreement with Tilray, Inc.; and development agreement with Cynapsus Therapeutics Inc. IntelGenx Technologies Corp. was founded in 2003 and is headquartered in Montreal, Canada.MiNK Therapeutics NASDAQ:INKT$23.25 +0.14 (+0.61%) Closing price 07/17/2025 04:00 PM EasternExtended Trading$22.09 -1.16 (-4.99%) As of 05:54 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. The company was incorporated in 2017 and is based in New York, New York. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas High-Flying GE Aerospace Drops After Blowout Q2 — What Now? A New $70 Billion AI Investment Could Push Taiwan Semiconductor Why Prologis May Be the Smartest Backdoor Bet on AI Real Estate Is Amazon Really the Best Forever Stock for Your Portfolio? Qualcomm: Undervalued Chip Stock in Breakout Uptrend Broadcom’s Takes on NVIDIA: Why Tomahawk Ultra Could Boost Shares CrowdStrike Bulls Beware: This Trade May Be Getting Crowded AMD Just Triggered a Signal Traders Can’t Ignore Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
